FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
17.25
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NeoGenomics, Inc. - Common Stock
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
September 01, 2021
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Earnings Scheduled For August 12, 2021
↗
August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...
Via
Benzinga
NeoGenomics, inc (NEO) Q2 2021 Earnings Call Transcript
↗
August 06, 2021
NEO earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance
↗
August 06, 2021
NeoGenomics Inc (NASDAQ: NEO) reported Q2 revenue of $122 million, +40% Y/Y, beating the consensus of $118.16 million. Clinical Services revenue of $101 million...
Via
Benzinga
Recap: NeoGenomics Q2 Earnings
↗
August 06, 2021
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01),...
Via
Benzinga
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
August 06, 2021
Second-Quarter 2021 Results and Highlights: - Consolidated revenue increased 40% to $122 million - Clinical Services revenue increased 37% to $101 million - Pharma Services revenue increased 55% to $20...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
July 14, 2021
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Recap: NeoGenomics Q1 Earnings
↗
May 05, 2021
Shares of NeoGenomics (NASDAQ:NEO) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 100.00% year...
Via
Benzinga
Earnings Scheduled For August 6, 2021
↗
August 06, 2021
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million....
Via
Benzinga
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
June 18, 2021
- Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
↗
June 03, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had...
Via
Benzinga
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
May 27, 2021
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
These 7 Medical Stocks Are Breaking Down — The Sell Rule You Should Know
↗
May 13, 2021
Former high-flyers Dexcom and Tandem Diabetes are among seven health care stocks breaking down right now, according to MarketSmith.com.
Via
Investor's Business Daily
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
May 10, 2021
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Neogenomics Inc (NEO) Q1 2021 Earnings Call Transcript
↗
May 05, 2021
NEO earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For May 13, 2021
↗
May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •...
Via
Benzinga
NeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For $390M
↗
May 05, 2021
NeoGenomics Inc (NASDAQ: NEO) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in...
Via
Benzinga
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
May 05, 2021
First-Quarter 2021 Results and Highlights: - Consolidated revenue increased 9% to $116 million - Clinical Services revenue increased 4% to $96 million - Pharma Services revenue increased 46% to $19...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
May 05, 2021
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
April 19, 2021
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
↗
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Cramer Advises Viewers On JetBlue Airways, MP Materials And More
↗
April 16, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would own JetBlue Airways Corporation (NASDAQ: JBLU). If it drops $2, he would buy more. Big Lots, Inc. (...
Via
Benzinga
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 13, 2021
FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021
April 07, 2021
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
< Previous
1
2
...
13
14
15
16
17
18
19
20
Next >
